Latest Commercialization Strategy News

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.

State Gas Limited clears a year-long ATO review to access $4.1 million in R&D tax concessions, enabling debt repayment and bolstering cash reserves. Meanwhile, independent certification of 30.2 petajoules of 2P gas reserves at Rolleston West strengthens its development prospects.

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.

Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.

ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

Imricor Medical Systems expands its US market reach with FDA 510(k) clearances for pediatric use of its NorthStar system and Vision-MR Diagnostic Catheter, enabling radiation-free cardiac catheterisations for children.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.